- Home
- SPRO
as 03-25-2025 2:33pm EST
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 45.7M | IPO Year: | 2017 |
| Target Price: | $5.00 | AVG Volume (30 days): | 112.8K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.73 - $1.81 | Next Earning Date: | 03-27-2025 |
| Revenue: | $47,977,000 | Revenue Growth: | -53.77% |
| Revenue Growth (this year): | -36.22% | Revenue Growth (next year): | -95.67% |
Stock Insider Trading Activity of Spero Therapeutics Inc. (SPRO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mahadevia Ankit | SPRO | Director | Feb 5 '25 | Sell | $0.78 | 69,219 | $53,990.82 | 689,866 | |
| Keutzer Timothy | SPRO | Chief Operating Officer | Feb 3 '25 | Sell | $0.78 | 56,537 | $44,098.86 | 794,002 | |
| Rajavelu Esther | SPRO | CFO & CBO | Feb 3 '25 | Sell | $0.78 | 20,689 | $16,137.42 | 724,720 | |
| Shukla Sath | SPRO | CEO & President | Feb 3 '25 | Sell | $0.78 | 155,333 | $121,159.74 | 1,736,883 |
Latest Spero Therapeutics Inc. News
SPRO Breaking Stock News: Dive into SPRO Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025
GlobeNewswire
a month ago
UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
GlobeNewswire
a month ago
Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
Zacks
2 months ago
Spero Therapeutics (SPRO) Upgraded to Buy: Here's What You Should Know
GlobeNewswire
3 months ago
Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes
Zacks
3 months ago
Here's Why Arcutis Stock More Than Doubled in Market Value in One Year
Zacks
3 months ago
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA
Zacks
3 months ago
Neumora Stock Hits Record Low on Depression Drug Study Failure
Compare SPRO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SPRO Spero Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.